Regenics works with Charles Rivers, Copenhagen, in the EU funded R&D project AquaHeal 3D under the EU Horizon 2020 Blue Bio Cofund international funding scheme. The project is funded from 2020-2023.

For more than 70 years, Charles River (US)  have seen technologies advance and new diseases emerge. Our one-man laboratory has evolved into a worldwide support network, allowing us to act as a steadfast partner to our clients, from discovery to lot release testing. By carefully cultivating our portfolio, our growth has become a continuous strategic effort in anticipating tomorrow’s drug development needs. While we can’t predict what the future holds, we continue to kindle the spark that inspired our founding: an urgency to advance human health by supporting our clients’ research every step of the way.

Regeniucs will primarily collaborate with Charles River, Copenhagen.

Charles River’s Coipenhagen site is in Ejby, Denmark. The facility performs general toxicology and specialized studies which include DART, juvenile toxicology, and wound healing, just to name a few. The facility also supports safety pharmacology programs and laboratory sciences support services.

Charles Ribvers Copenhagen are 400 emplyees and deploy 

• 455+ large animal rooms with floor pens • 25+ multispecies (rodent) rooms
• 2 surgical suites
• 7,500 m2/80,700 ft2



Contact information:


Hestehavevej 36 A,

4623 Lille Skensved,



+46 8 511 888 00 | email :

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.